I hope it's a large phase I study in which they can look for early efficacy signals, rather than just safety.
Unlike trials for cancer therapeutics, regenerative medicines etc which can take years to measure efficacy; trialing a cholesterol lowering compound should be relatively fast due to massive number of possible patients, simple to measure endpoints, and short trial duration.
Surely NYX-PCSK9i would attract better licensing terms with human efficacy data behind it. I'd want to see 12-15% royalties on 5-10B USD per year.
On another note, my hunch is that Pfizer want to re-secure dominance in the cholesterol lowering market - they have to be the most likely suitor.
NYR Price at posting:
31.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)